Compositions and methods for modulating an immune response

• US 10,556,006 B2
• Filed: 09/27/2017
• Issued: 02/11/2020
• Est. Priority Date: 08/28/2008
• Status: Active Grant

• Current Assignee: HTYR Acquisition LLC
• Original Assignee: Taiga Biotechnologies, Inc.
• Inventors: Refaeli, Yosef, Turner, Brian Curtis
• Primary Examiner(s): White, Nicole Kinsey
• Application Number:
  US15/717,675
• Publication Number:
  US 20180092972A1
• Time in Patent Office: 867 Days
• Field of Search: None
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/06 for tuberculosis
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/001 by chemical synthesis
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/82 Translation products from oncogenes
• CPC Class Codes: C07K 2319/02 containing a signal sequence
• CPC Class Codes: C07K 2319/21 : containing a His-tag
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed herein are methods of modulation of the viability of a cell using fusion proteins comprising a transporter peptide sequence and a MYC polypeptide. Further disclosed herein are methods of modulating an immune response using the fusion proteins. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.

Claims

1. A method of treating a viral infection, comprising administering to an individual in need thereof a fusion peptide comprising:

a. a transporter peptide sequence; and

b. a MYC polypeptide sequence,

wherein the transporter peptide sequence transports the fusion peptide into the nucleus of an immune cell in the individual.

2. The method of claim 1, wherein the fusion peptide enhances the immune response against the virus.

3. The method of claim 1, wherein the immune cell is a primary lymphocyte.

4. The method of claim 1, wherein the individual has a decreased immune response to the virus in the absence of the fusion peptide.

5. The method of claim 1, wherein the virus is selected from the group consisting of hepatitis A;

hepatitis B;

polio;

measles;

mumps;

rubella;

influenza;

varicella zoster virus;

rotavirus;

smallpox;

yellow fever; and

human papillomavirus.

6. The method of claim 1, wherein the virus is an influenza virus.

7. The method of claim 5, further comprising administering a vaccine for the virus.

8. The method of claim 1, wherein the fusion peptide has Formula (I):

transporter peptide sequence-MYC sequence.

9. The method of claim 1, wherein the fusion peptide has Formula (II):

transporter peptide sequence-X-MYC sequence,

wherein —

X—

is at least one molecule that links the transporter peptide sequence and the MYC sequence.

10. The method of claim 1, wherein the fusion peptide has Formula (II):

transporter peptide sequence-X-MYC sequence, wherein in X is at least one amino acid.

11. The method of claim 1, wherein the fusion peptide is administered orally, parenterally, intranasally, buccally, rectally, or intravenously.

12. The method of claim 1, wherein the fusion peptide is administered intramuscularly, subcutaneously, topically or transdermally.

13. The method of claim 1, wherein the fusion peptide is formulated as a delayed release formulation or as an extended release formulation.

14. A method of increasing an immune response to a virus, comprising administering to an individual that has been exposed to a viral antigen from the virus a fusion peptide comprising:

a. a transporter peptide sequence; and

b. a MYC polypeptide sequence,

wherein the transporter peptide sequence transports the fusion peptide into the nucleus of an immune cell in the individual.

15. The method of claim 14, wherein the individual has a decreased immune response to the virus in the absence of the fusion peptide.

16. The method of claim 14, wherein the virus is selected from the group consisting of hepatitis A;

hepatitis B;

polio;

measles;

mumps;

rubella;

influenza;

varicella zoster virus;

rotavirus;

smallpox;

yellow fever; and

human papillomavirus.

17. The method of claim 16, wherein the virus is an influenza virus.

18. The method of claim 16, further comprising administering a vaccine for the virus.

19. The method of claim 14, wherein the fusion peptide is administered orally, parenterally, intranasally, buccally, rectally, or intravenously.

20. The method of claim 14, wherein the fusion peptide is administered intramuscularly, subcutaneously, topically or transdermally.